BACKGROUND & AIMS: Signaling by the mammalian target of rapamycin complex 1 (mTORC1) has been implicated in various human cancers. mTORC1 signaling is activated in intestinal tumors of adenomatous polyposis coli (Apc(Δ716)) mice, a model of familial adenomatous polyposis; in these mice, the mTORC1 inhibitor RAD001 can block tumor formation. However, the precise mechanism of mTORC1 signaling in intestinal tumors is not clear. We investigated whether c-Jun-NH(2) terminal kinase (JNK) is involved in the mTORC1 activation. METHODS: We investigated the effects of an inhibitor and an activator of JNK, as well as small interfering RNA against JNK, on mTORC1 in Apc(Δ716) mice and colon cancer cell lines. We also determined the role of JNK in mTORC1 signaling using in vitro kinase assays. RESULTS: JNK was activated in intestinal polyps of Apc((Δ716) mice); the JNK inhibitor SP600125 significantly suppressed tumor formation. In colorectal cancer cell lines, the JNK activator anisomycin activated mTORC1, whereas SP600125 or small interfering RNAs against JNK suppressed signaling. Importantly, JNK stimulated the mTORC1 kinase activity in vitro, through direct phosphorylation of Raptor at serine 863. CONCLUSIONS: JNK is required for activation of mTORC1 in intestinal tumor cells. JNK inhibitors might be developed as therapeutics or to prevent development of intestinal tumors.
BACKGROUND & AIMS: Signaling by the mammalian target of rapamycin complex 1 (mTORC1) has been implicated in various humancancers. mTORC1 signaling is activated in intestinal tumors of adenomatous polyposis coli (Apc(Δ716)) mice, a model of familial adenomatous polyposis; in these mice, the mTORC1 inhibitor RAD001 can block tumor formation. However, the precise mechanism of mTORC1 signaling in intestinal tumors is not clear. We investigated whether c-Jun-NH(2) terminal kinase (JNK) is involved in the mTORC1 activation. METHODS: We investigated the effects of an inhibitor and an activator of JNK, as well as small interfering RNA against JNK, on mTORC1 in Apc(Δ716) mice and colon cancer cell lines. We also determined the role of JNK in mTORC1 signaling using in vitro kinase assays. RESULTS:JNK was activated in intestinal polyps of Apc((Δ716) mice); the JNK inhibitor SP600125 significantly suppressed tumor formation. In colorectal cancer cell lines, the JNK activator anisomycin activated mTORC1, whereas SP600125 or small interfering RNAs against JNK suppressed signaling. Importantly, JNK stimulated the mTORC1 kinase activity in vitro, through direct phosphorylation of Raptor at serine 863. CONCLUSIONS:JNK is required for activation of mTORC1 in intestinal tumor cells. JNK inhibitors might be developed as therapeutics or to prevent development of intestinal tumors.
Authors: Irina A Vasilevskaya; Muthu Selvakumaran; Lucia Cabal Hierro; Sara R Goldstein; Jeffrey D Winkler; Peter J O'Dwyer Journal: Clin Cancer Res Date: 2015-05-28 Impact factor: 12.531
Authors: X Xie; T S Kaoud; R Edupuganti; T Zhang; T Kogawa; Y Zhao; G B Chauhan; D N Giannoukos; Y Qi; D Tripathy; J Wang; N S Gray; K N Dalby; C Bartholomeusz; N T Ueno Journal: Oncogene Date: 2016-12-12 Impact factor: 9.867
Authors: Jatin Roper; Mark J Sinnamon; Erin M Coffee; Peter Belmont; Lily Keung; Larissa Georgeon-Richard; Wei Vivian Wang; Anthony C Faber; Jihye Yun; Ömer H Yilmaz; Roderick T Bronson; Eric S Martin; Philip N Tsichlis; Kenneth E Hung Journal: Cancer Lett Date: 2014-02-24 Impact factor: 8.679